Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline
Scott C. Morgan(University of Ottawa), Howard M. Sandler(Cedars-Sinai Medical Center), Mark K. Buyyounouski(Palo Alto University), Jason A. Efstathiou(Massachusetts General Hospital), Caroline Delbourgo Patton(American Society for Radiation Oncology), Daniel A. Barocas(Vanderbilt University Medical Center), Daniel W. Lin(University of Washington), C.M. Leyrer(Wake Forest University), Søren M. Bentzen(University of Wisconsin–Madison), Per H. Halvorsen(Lahey Medical Center), Patrick Greany, Karen E. Hoffman(The University of Texas MD Anderson Cancer Center), Michael Chang(Thomas Jefferson University), C.A. Lawton(Medical College of Wisconsin), D.A. Loblaw(American Society of Clinical Oncology), Michael E. Ray(ThedaCare), Bridget F. Koontz(AdventHealth Orlando)
Cited by 243
Related Papers
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial
|Neuro-Oncology|2013|942
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656
Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline
|Practical Radiation Oncology|2018|615
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592